

CONCEPT-TO-CLINIC

Center for Targeted Therapy

Liposomal-NDD-Platinum Combination Demonstrates Potential

“**D**isease stabilization has been achieved for every patient treated thus far in an M. D. Anderson Phase I study of Aroplatin™,” said Luis H. Camacho, M.D., assistant professor in the Phase I Program/Division of Cancer Medicine and principal investigator of the trial.

L-NDDP [cis-bis neodecanoato-trans-R, R-1, 2 diaminocyclohexane platinum (II)], or Aroplatin, is a liposomal formulation of a third-generation, DACH (diaminocyclohexane) platinum agent developed more than 20 years ago by Drs. Abdul Khokhar, Ph.D. and Gabriel Lopez-Berestein, M.D., both professors in the Department of Experimental Therapeutics, and Roman Perez-Soler, M.D., then a fellow in the Department of Medical Oncology.




Figure 1

“Dr. Lopez and I developed L-NDDP – on a napkin over a coffee table – many years ago at an AACR meeting,” said Khokhar. “L-NDDP was the first agent to make it entirely from bench-to bedside at M. D. Anderson.”

Aroplatin offers unique features not found in other platinum agents (i.e., cisplatin and carboplatin) due to its liposomal approach. L-NDDP (see Figure 1) is entrapped in a liposome – a tiny, drug-carrying sac that is composed of the same lipids that make up cell membranes – that is believed to allow for improved delivery of the agent, increased time and distribution within the body and a decrease of damage to healthy tissue.

L-NDDP was developed as a non-nephrotoxic, novel platinum drug with a broad spectrum of antitumor activity and non-cross resistance with Cisplatin. While


other platinum analogs are water-soluble and not appropriate for liposomal encapsulation, they also exhibit toxic side effects on the nervous system and kidneys. In addition, many solid tumors are resistant or, during treatment, become resistant to these platinum agents.

The Phase I trial is enrolling approximately 16 to 28 patients with advanced solid tumor malignancies or B-cell lymphoma and is taking place at M. D. Anderson and the Massachusetts General Hospital in Boston.

M. D. Anderson has seven patients enrolled in the study – six of whom have appendiceal carcinoma.

Primary objectives of the trial include determining the maximum tolerated dose and dose-limiting toxicity of

(continued on page 2)



Lecture Series • 9 a.m. • SBC Auditorium B2.4750

September 27, 2006.....**Sidney Pestka, Ph.D.**, Robert Woods Johnson Medical School

October 11, 2006.....**Jim Paulson, Ph.D.**, Scripps Research Institute

December 6, 2006....**Neal Rosen, M.D., Ph.D.**, Memorial-Sloan Kettering Cancer Center

Doors Open to Immunohistochemistry/Molecular Imaging Lab

The department has acquired a multi-mode inverted live cell microscope with a digital camera/imaging system that is housed in the new Immunohistochemistry/Molecular Imaging Lab.

This inverted microscope is capable of color and fluorescence-based applications (see Figure 2). Using fluorescence results in high illumination for a more detailed image and this highly advanced technology allows researchers to target specific proteins or structures within cells or on the membrane.

The Nikon-Eclipse TE2000 has a dark room chamber; TexasRed, DAPI and FITC filters; and time lapse capabilities. It can





Figure 2

accommodate culture flasks, plates, chambers and single glass slides. In addition, the microscope utilizes two digital imaging analysis software programs – ACT-1 and NIS-Elements.

Housed in Y8.5314, the new microscope will be used primarily by Suhendan Ekmekcioglu, Ph.D., assistant professor in the Department of Experimental Therapeutics, in her research on inducible nitric oxide synthase (iNOS) expression in melanoma cells and understanding the mechanism behind this uncontrolled expression of the protein.

If you are interested in more information on this new technology, please contact Dr. Suhendan Ekmekcioglu at (713) 563-0605 or through Lotus Notes.





Varsha Gandhi, Ph.D., in collaboration with **Michael Rosenblum, Ph.D.**, both professors in the Department of Experimental Therapeutics, recently received a Leukemia and Lymphoma Society Translational Research Award for her application, "BlyS-Gelonin: A Targeted Therapeutic for CLL." The award is scheduled to begin in October 2006.

Zhen Fan, M.D., associate professor in the Department of Experimental Therapeutics, had a recent article that was one of the top 10 articles viewed by the readership of Molecular Pharmacology in July 2006.



Published June 16, 2006, online ahead of print, in Molecular Pharmacology, a publication of the American Society for Pharmacology and Experimental Therapeutics, the article titled "Differential Roles of PDK1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin and Gemcitabine" can be viewed by visiting the following Web site <http://molpharm.aspetjournals.org/>.

Congratulations to the ET 3rd and 4th Quarter FY2006 Recognition Award recipients – **Xuhui Zhang, Babita Saigal, Pijus Mandal, Diana Quinones, Vanity McMurtry, Patsy Rodriguez, Lidia Vogelsang, Alcena Doxley, Dawn Banas, Brenita Tyler** and **Pearl Coleman** – for their demonstration of excellence and dedication to the Department of Experimental Therapeutics and M. D. Anderson Cancer Center!

These classified employees were selected by the ET Reward & Recognition Committee based on nominations that established qualities of teamwork and excellence in all they do.

PROMOTIONS

A job well done... The following ET employees were recently promoted: **Feng Meng**, senior research assistant, in Dr. Nicholas Donato's lab; **Melissa Rubalcaba**, senior financial analyst, in the Administrative Core; **Peiyong Yang, Ph.D.**, assistant professor, and **Mary Johansen, Pharm.D.**, associate professor, both in Dr. Robert Newman's lab; **Yinhua Yu, M.D.**, associate professor, in Dr. Robert Bast's lab; and **Geoffrey Bartholomeusz, Ph.D.**, assistant professor in Dr. Garth Powis' lab.

ET Thanksgiving Potluck Luncheon


Friday, November 17, 2006
11 a.m. to 1 p.m.

CPB, 8th Floor, Rooms 5 through 8

ET Holiday Party

Friday, December 1, 2006
7 p.m. to 11 p.m.

Courtyard on St. James Place
1885 St. James Place
Houston, Texas 77056



Liposomal-NDD-Platinum Combination Demonstrates Potential *(continued from page 1)*

L-NDDP; assessing the safety of the agent; and determining the pharmacokinetic profile of the compound. Nine previous preclinical studies have been conducted to test the *in-vivo* safety and efficacy of Aroplatin.

Treatments are given intravenously at dose levels starting at 100 mg/m² for five days, every 30 days. At this point, one patient has received five cycles of treatment (the most so far at M. D. Anderson) with no evidence of toxicity and two patients have presented with minor allergic reactions. Camacho plans to expand the trial and open a new cohort for patients with appendiceal mucinous carcinoma, collaborating with Paul F. Mansfield, M.D., professor in the Department of Surgical Oncology, Robert A. Wolff, M.D., associate professor, and Cathy Eng, M.D., assistant professor, both in the Department of Gastrointestinal Medical Oncology.

Zahid Siddik, Ph.D., professor in the Department of Experimental Therapeutics, is handling the pharmacokinetic analysis for the Phase I trial and said, "We have developed the methodology to assess the PK of this very lipophilic and protein-bound agent and are in the process of both validating that methodology and applying it to the PK analysis." Though it is too early to mention any results, Siddik anticipates that the findings will define the relationship of PK to toxicity and antitumor response, which will then allow therapeutic application of Aroplatin to be optimized.

The study, which began in December 2005, is expected to last approximately one year and according to Camacho, "We expect that by using liposomal-NDDP, we will have greater penetration into the tumor and tissue and achieve better activity."

For more information regarding the Phase I trial, please contact Dr. Luis Camacho through Lotus Notes. Aroplatin is licensed by Antigenics.



Bryant Darnay, Ph.D., assistant professor in the Department of Experimental Therapeutics, will make an oral presentation titled, "Site-specific TRAF6 Auto-ubiquitination via Lys63 Linkages Connects RANK to Osteoclastogenesis," authors – Lamothe B, Besse A, Webster WK, Campos A, Wu H and Darnay BG; and will present a poster titled, "The TAB2/TAB3-TAK1 Interaction is Required for RANKL-induced Signaling and Osteoclastogenesis," authors – Besse A, Lamothe B, Campos A, Webster WK and Darnay BG – both at the 28th Annual Meeting of the American Society for Bone and Mineral Research, Sept. 15 to 19, 2006 in Philadelphia.

Mei Koh, Ph.D., a research scientist in Dr. Garth Powis' lab, presented a poster titled, "SART1/HAF, a protein widely over expressed in human cancer decreases HIF-1 α levels and inhibits tumor growth" at the Molecular Therapeutics of Cancer Gordon Research Conference held July 16 to 21, 2006 at The Queen's College in Oxford, UK.

Held annually since 1978, GRC provides an interactive forum for the presentation and discussion of novel drugs, drug targets and the preclinical and clinical development of novel therapeutics. Presentations are based on unpublished data and allow for a unique opportunity for feedback and interactions among individuals from academia, industry and clinical areas.

Varsha Gandhi, Ph.D., professor in the Department of Experimental Therapeutics, presented "Using Cellular Pharmacology in the Evaluation of New Agents" at the Satellite Symposium of the Annual European Hematological Society Meeting in Amsterdam held June 15, 2006.



Julie Izzo, M.D., assistant professor in the Department of Experimental Therapeutics, has been invited to speak at the International Society of Gastrointestinal Oncology 2006 Annual Meeting. She will present "Emerging Science: Molecular Targets in Esophageal Cancer" at the meeting Sept. 21 to 23, 2006, in Arlington, Va.

Bharat B. Aggarwal, Ph.D., professor in the Department of Experimental Therapeutics, presented "Targeting Inflammation by Dietary Agents for Prevention and Treatment of Cancer" at Cancer Prevention in the 21st Century June 27, 2006 in Serdang, Malaysia.

Additionally, Dr. Aggarwal was invited to speak at the 6th International Workshop on Micronutrients, Oxidative Stress and the Environment June 29 to July 2, 2006 in Kuching, Malaysia, where he presented "Targeting Inflammation by Tocotrienols & Other Dietary Agents for Prevention and Treatment of Cancer."



Kapil Mehta, Ph.D., professor in the Department of Experimental Therapeutics, participated in the organization of "The CD38 Ecto-enzyme Family: Advances in Basic Science and Clinical Practice" held June 8 to 10, 2006 in Torino, Italy.

The meeting featured the roles in biology and disease of CD38 and CD157 and other NAD-utilizing ectoenzymes and included sessions on NAD metabolism, NAD-derived signaling molecules and roles in immunoregulation and diseases, with special attention to chronic lymphocytic leukemia.

Dr. Mehta presented "Implications of retinoid-induced CD38 antigen in myeloid leukemias." Dr. Michael Keating, a professor in the Department of Leukemia, also presented at the conference. Other conference organizers include Fabio Malavasi of Torino, Italy; Armando Genazzani of Novara, Italy; and Frances Lund of Saranac Lake, N.Y.

Zhen Fan, M.D., associate professor in the Department of Experimental Therapeutics, delivered a lecture titled "Hypoxia inducible factor-1 as a rationalized co-target for epidermal growth factor receptor-targeted cancer therapy" at the 4th Annual Congress of International Drug Discovery Science and Technology, held May 25 to June 2, 2006, in Dalian, China.

The Pharmaceutical Development Center will present at Institutional Grand Rounds

Friday, October 6, 2006

Noon to 1 p.m.

Hickey Auditorium, R11.1400

History and Growth of the Pharmaceutical Development Center

Timothy Madden, Pharm.D.

Associate Professor, Department of Experimental Therapeutics
Co-Director, PDC

Development of siRNA Therapy for the Treatment of Cancer

Gabriel Lopez-Berestein, M.D.

Professor, Department of Experimental Therapeutics
Executive Director, PDC

RTA744 – A Novel Blood - Brain Barrier Penetrating Anthracycline

Waldemar Priebe, Ph.D.

Professor, Department of Experimental Therapeutics

Development of Oleander Extract for Treatment of Solid Tumors: Progress Toward a Phase I Clinical Trial

Robert A. Newman, Ph.D.

Professor, Department of Experimental Therapeutics
Co-Director, PDC

Pharmaceutical Development Center: Current Status and Future Plans of the PDC

Garth Powis, D.Phil.

Professor and Chair, Department of Experimental Therapeutics
Director, Center for Targeted Therapy

ORA Reminder...

Institutional Research Grant Program applications for funding are due on **Monday, Oct. 3, 2006**, in the Office of Research Administration (HMB7.060).

Applications must be complete with no errors by October 3 – corrections after the deadline are no longer allowed. If submitted to ORA by Sept. 25, 2006, they will review your application for completeness, if you like.

The new revised application and guidelines for this program are located on the ORA Web site through “funding opportunities.” Please use the application dated Feb. 10, 2006.

If you have any questions, please contact April Kral, grant program manager in the Department of Experimental Therapeutics, at extension 5-0132 or through Lotus Notes.

Paperless Paystubs

Do you have direct deposit and wish you could stop receiving that paper paystub each payday? More than 2,600 of your co-workers are already doing it. Now you can, too. Go paperless by requesting to access your paystub online instead of receiving a paper direct deposit form.

View your paystub online at [MyHR](#), a secure intranet site, accessible with your own personal login and password. Your information is posted at MyHR four days before each payday. MyHR allows you to print your paystub when needed. Or you can convert it to a PDF file to send to a personal e-mail account to print at home.

If you'd like to stop receiving paper paystubs, send a Lotus Notes e-mail to “Payroll Services,” stating that you'd like to go paperless. Be sure to include your employee ID number.

For more information, visit the [Payroll](#) intranet site.
Taken from the June 5, 2006 issue of Employee Notes.

ESL Classes for Professional Development

English as a Second Language classes are offered through the Department of Human Resources at The University of Texas M. D. Anderson Cancer Center to enhance an employee's communication abilities at work and in professional and personal situations.

Designed to complement the technical expertise of employees, these classes have been developed by the University of Houston's Accelerated Learning Program specifically for employees at M. D. Anderson.

Courses are offered in writing, grammar, pronunciation, speaking naturally, effective communication in the workplace, and effective presentation and meeting skills.

Available to all faculty, employees, fellows and students working at M. D. Anderson, these ESL classes are free of charge.

Registration is from 11 a.m. to 2 p.m. and from 4 p.m. to 5:30 p.m. in The Park located in the Alkek Building on the following dates: Dec. 5 to 7, 2006, March 6 to 8, 2007 and May 22 to 24, 2007. Participants are encouraged to register in person for coaching and evaluation.

For more information, please contact Mercedes Suraty-Clarke, program director at the University of Houston, at (713) 743-1185 or msclarke@uh.edu or visit <http://hr.mdanderson.org/depts/ed/languageskills/>.

Electronic Institutional Biosafety Committee Database

An electronic Institutional Biosafety Committee database is now in place, replacing the paper-based chemical/biochemical and rDNA forms, to facilitate the electronic submission and review process for research protocols involving the use of potentially hazardous agents.

Developed by the Office of Research Administration, with guidance from the Institutional Biosafety Committee, the e-IBC was released on Sept. 1, 2006 for institution-wide implementation. Hard-copy registration forms will be accepted until Dec. 25, 2006.

e-IBC training classes are scheduled over the next several months. For more information on e-IBC, please contact Juan Alejandro at extension 3-3879.

TRAINEE NEWS

GSA Elects New Officers

The 2006-2007 officers for the Graduate Student Association of The University of Texas Graduate School of Biomedical Sciences at Houston are: **Patrick Gibney**, president; **Brett Chiquet**, vice president; and **Nicole Bohnenstiehl**, secretary.

Gibney is a fourth year microbiology/molecular genetics student and can be reached at (713) 500-5894 or patrick.a.gibney@uth.tmc.edu.

Chiquet is third year student in the D.D.S. and Ph.D. programs. He can be reached at (713) 500-5786 or brett.t.chiquet@uth.tmc.edu.

Bohnenstiehl is a fourth year student in molecular pathology and can be reached at (713) 792-0705 or nicole.l.bohnenstiehl@uth.tmc.edu.

PEOPLE NOTES

Nga Bich Thi Nguyen joined Dr. Robert Newman's lab in July as a research assistant I. She is located at El Rio (ER1.301) and can be reached by phone at (713) 745-3220.

Effective Sept. 1, 2006, **Arup Chakraborty, Ph.D.**, joined Dr. Waldemar Priebe's lab as assistant professor; **Feng Meng**, senior research assistant, and **Ji Wu, M.D.**, instructor, transferred to Dr. Razelle Kurzrock's lab; and **Yuling Chen** will join Dr. Bill Plunkett's lab as a senior research assistant on Sept. 5, 2006

Robert Lemos will become a member of Dr. Garth Powis' lab on September 25, 2006, as a research assistant II.

Please check the departmental phone list or Lotus Notes for contact information.

Biochemical Pharmacology

Molecular targets of dietary agents for prevention and therapy of cancer.

Aggarwal BB, Shishodia S.

Biochem Pharmacol. 2006 May 14;71(10):1397-421. Epub 2006 Feb 23. Review.

Cancer Research

Aptamer:toxin conjugates that specifically target prostate tumor cells.

Chu TC, Marks JW 3rd, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, Levy M.

Cancer Res. 2006 Jun 15;66(12):5989-92.

High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.

Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, Mao L, Wistuba I, Strieter RM, Kurie JM.

Cancer Res. 2006 Apr 15;66(8):4198-207.

Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.

Cunningham MP, Thomas H, Fan Z, Modjtahedi H.

Cancer Res. 2006 Aug 1;66(15):7708-15.

Cell

Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosis.

Chandra D, Bratton SB, Person MD, Tian Y, Martin AG, Ayres M, Fearnhead HO, Gandhi V, Tang DG.

Cell. 2006 Jun 30;125(7):1333-46.

Chemical Communications

Fullerene (C(60)) immunoconjugates: interaction of water-soluble C(60) derivatives with the murine anti-gp240 melanoma antibody.

Ashcroft JM, Tsyboulski DA, Hartman KB, Zakharian TY, Marks JW, Weisman RB, Rosenblum MG, Wilson LJ.

Chem Commun (Camb). 2006 Jul 28;(28):3004-6. Epub 2006 Jun 9.

Clinical Cancer Research

Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.

Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ.

Clin Cancer Res. 2006 Jul 1;12(13):4011-7.

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK; AACR Task Force on Cancer Prevention.

Clin Cancer Res. 2006 Jun 15;12(12):3661-97.

Current Cancer Therapy Reviews

TNF blockade: an inflammatory issue.

Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H.

Ernst Schering Res Found Workshop. 2006;(56):161-86. Review.

International Journal of Cancer

Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).

Chakravarti N, Myers JN, Aggarwal BB.

Int J Cancer. 2006 Sept 15; 119(6):1268-1275.

Journal of Biological Chemistry

Genetic deletion of NAD(P)H:quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis.

Ahn KS, Sethi G, Jain AK, Jaiswal AK, Aggarwal BB.

J Biol Chem. 2006 Jul 21;281(29):19798-808. Epub 2006 May 8.

Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.

Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB.

J Biol Chem. 2006 Mar 3;281(9):5612-22. Epub 2005 Dec 23.

Molecular Cancer Therapeutics

Implications of tissue transglutaminase expression in malignant melanoma.

Fok JY, Ekmekcioglu S, Mehta K.

Mol Cancer Ther. 2006 Jun;5(6):1493-503.

Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression.

Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, Aggarwal BB.

Mol Cancer Ther. 2006 Jun;5(6):1434-45.

Oncogene

Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression.

Shishodia S, Aggarwal BB.

Oncogene. 2006 Mar 9;25(10):1463-73.

Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.

Herman JF, Mangala LS, Mehta K.

Oncogene. 2006 May 18;25(21):3049-58.

INTRODUCING...



Name: John McMurray
Title: Associate Professor
Departmental Role: 1) research faculty; 2) chair of Chemistry Core Facility. Also director of Nuclear Magnetic Resonance (NMR) Facility
Birthplace: Erie, Pennsylvania

- The word that best describes me is:** Overbooked
- My proudest accomplishment is:** I play classical guitar and am actually "pretty good."
- People who know me would say:** I am a walking chemical encyclopedia and that I have a great sense of humor.
- When not working for a living:** I catch up on my sleep, go sailing, play guitar and spend time with my wife and kids.
- Favorite or recent movies:** "Wallace and Gromit: The Curse of the Were-Rabbit" – most recent, but definitely not a favorite
- Favorite or recent books:** "How the Scots Invented the Modern World" by Arthur Herman.
- The most unique thing about me is:** My genetic code.
- Favorite quote(s):** "Patience comes to he who waits." from Gilbert & Sullivan's "H.M.S. Pinafore"
- Favorite song(s):** Grand Sonata for Violin & Guitar in A major by Niccolò Paganini
- What I like most about Houston:** There are many diverse activities – anything from outdoor sports to cultural events.
- What I like least about Houston:** The ghastly climate.
- Something most people don't know about me:** If I wanted them to know, I would have told them.



In Memoriam

Kay Ellison Biescar, 58, passed away on July 15, 2006, of brain cancer.

Many of you knew Kay from her days in the Department of Experimental Therapeutics during Dr. Zahid Siddik's tenure as ad interim chair. She began her career at M. D. Anderson in 1996 as executive assistant to Dr. John Mendelsohn and was promoted in 2000 to office manager of ET. In January 2005, Kay moved on to become operations manager in the Department of Surgical Oncology.



Kay Ellison Biescar
1947 – 2006

Kay was strongly devoted to her duties at M. D. Anderson – she worked hard, arriving early and leaving late. She was organized and disciplined and had a masterly command of procedures and protocols.

The Melody Lingers On...

Zahid Siddik (inspired by "I'm Free" – Anonymous)

*Don't grieve for Kay, for now she's free
 She is following the path Heaven has laid you see.
 She took the path when she heard the call
 And had no choice when she left us all.*

*She could not stay another day
 To laugh, to love, to work and to play.
 Tasks left undone must stay that way
 She found peace at the close of day.*

*Although her parting has left a void
 We must fill it with remembered joy.
 A friendship shared, a laugh, a kiss
 Oh yes, these things we will dearly miss.*

*We must not be burdened with times of sorrow
 How she wished us the sunshine of tomorrow!
 Her life was full, she savored much
 Good friends, good times, a loved one's touch.*

*Perhaps her time seemed all too brief
 Don't lengthen it now with undue grief.
 Let's lift up our hearts although she is gone
 Do remember: "The song is ended, but the melody lingers on..."*

Kay made things happen: organizing the ET seminar series for the first time, having old offices re-furnished, handling visa issues and the list goes on.

Most of all, Kay always worked with her door open and was easily accessible. A steady stream of people moved in and out of her office every day. Kay was good with people. She was open and spontaneous. She had a huge smile and her eyes lit up when she was amused. Kay's laugh was infectious and she was always ready with jokes to lighten up moody days.

*Contributed by: Zahid Siddik,
 David Farquhar and Julie Izzo.*

Concept-to-Clinic is a publication of the Department of Experimental Therapeutics at The University of Texas M. D. Anderson Cancer Center.

Published quarterly, we welcome submissions from members of the department and reserve the right to edit for length and style.

Please send submissions to:
 Kim Antley, kmantley@mdanderson.org
 Phone: 713-792-1468

Chair

Garth Powis, D.Phil.

Department Administrator

Kristen Anderson

Editor

Kim Antley

Newsletter Committee

Timothy Madden, Pharm.D., Chair
 Bharat Aggarwal, Ph.D.
 Debra Brown
 Varsha Gandhi, Ph.D. (ex-officio)
 Julie Izzo, M.D.
 Bahareh Tavarna

Department of Experimental Therapeutics-Unit 422
 The University of Texas
 M. D. Anderson Cancer Center
 1515 Holcombe Blvd
 Houston, Texas 77030-4009

Non-Profit Org.
 U.S. Postage
 PAID
 Permit No. 7052
 Houston, TX